MYGN Shares Outstanding History
Below is a table of the MYGN shares outstanding history going back to 1/29/2010:

Date MYGN Shares Outstanding
1/29/201096.43M
4/30/201097.78M
8/9/201094.07M
10/29/201092.38M
1/28/201189.88M
4/29/201185.74M
8/9/201185.09M
10/28/201184.73M
1/27/201284.29M
4/27/201284.87M
8/6/201281.69M
11/1/201281.40M
1/31/201380.58M
5/2/201379.65M
8/1/201380.45M
11/7/201374.75M
1/31/201472.97M
5/2/201474.82M
8/1/201472.80M
10/30/201472.99M
1/29/201571.12M
4/30/201569.45M
7/31/201568.60M
10/29/201569.77M
1/29/201671.25M
4/29/201670.30M
8/1/201669.13M
10/27/201668.42M
2/2/201768.09M
4/27/201768.12M
8/3/201768.44M
11/2/201769.24M
2/1/201869.85M
5/4/201869.91M
8/20/201870.92M
11/2/201874.76M
1/31/201973.27M
5/1/201973.37M
8/8/201973.87M
7/9/20194.31M
11/4/201974.39M
1/31/202074.55M
5/1/202074.55M
8/7/202074.71M
11/2/202075.21M
3/9/202176.30M
4/28/202177.05M

Also see: MYGN Market Cap History
MYGN YTD Return
MYGN Historical Shares Outstanding:
-1.97% CAGR
MYGN Historical Shares Outstanding: +-1.97% CAGR

Mouse over chart for data details
1/29/2010 ...4/28/2021
Myriad Genetics is precision medicine company acting as an advisor to transform patient lives through molecular diagnostics. Co.'s molecular diagnostic tests are designed to analyze genes, their expression levels and corresponding proteins to assess an individual's risk for developing disease later in life, diagnose disease, determine a patient's likelihood of responding to a particular drug, or disease recurrence and assess a patient's risk of disease progression. Co. also provides biomarker discovery and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries utilizing its multiplexed immunoassay technology. We show 47 historical shares outstanding datapoints in our coverage of MYGN's shares outstanding history.

Understanding the changing numbers of MYGN shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like MYGN versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching MYGN by allowing them to research MYGN shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes
Get Free SEC filing alerts for MYGN:
MYGN SEC Filing Email Alerts ServiceExternal link
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Myriad Genetics (MYGN) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

MYL Shares Outstanding History
MYND Shares Outstanding History
MYOK Shares Outstanding History
NAOV Shares Outstanding History
NBIX Shares Outstanding History
NDRA Shares Outstanding History
NEO Shares Outstanding History
NEOG Shares Outstanding History
NEOS Shares Outstanding History
NERV Shares Outstanding History
More Healthcare companies »

 

MYGN Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2021, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.